RHHBF

ABBV AMGN AMGN:CA BAYRY BAYZF Biotechnology BMY GILD IPSEF IPSEY JNJ JNJ:CA LLY LLY:CA NONOF NOVO:CA NVO NVON:CA NVS NVS:CA NVSEF PFE PFE:CA REGN RHHBF RHHBY RHHVF Robert J. Lake ROCH:CA ROG:CA SAN:CA SNY SNY:CA SNYNF Uncategorized VRTX ZLLY:CA ZPFE:CA

Regeneron: Fairly Valued Now After A Stellar Upswing

Mar 11, 2026

Biotechnology RHHBF RHHBY Uncategorized ZLDPF

Roche succeeds in mid-stage trial for obesity drug developed with Zealand

Mar 5, 2026

Biotechnology BMY BMYMP CELG.RT NONOF NOVO:CA NVO NVON:CA PRTA RHHBF RHHBY RHHVF ROCH:CA ROG:CA Terry Chrisomalis Uncategorized

Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution

Mar 3, 2026

Biotechnology RHHBF RHHBY RXRX Uncategorized

Recursion jumps after solid Q4 beat

Feb 25, 2026

ABBV AZN Biotechnology RHHBF RHHBY Uncategorized

AbbVie wins FDA nod for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia

Feb 20, 2026

Biotechnology BYDDF ESLOF GALDY GVDBF HDLMY HLBZF LIN LNVGF LNVGY MHVYF MTD RHHBF RHHBY RHHVF RYAOF SDVKF SFGYY TKOMF TKOMY TT Uncategorized UNCFF UNCRY ZLAB

ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025

Feb 4, 2026

Biotechnology NVS NVSEF OLMA PFE RHHBF RHHBY Uncategorized

Roche boosts Olema after additional late-stage trial data for breast cancer drug

Dec 10, 2025